JP2016512554A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512554A5 JP2016512554A5 JP2016501801A JP2016501801A JP2016512554A5 JP 2016512554 A5 JP2016512554 A5 JP 2016512554A5 JP 2016501801 A JP2016501801 A JP 2016501801A JP 2016501801 A JP2016501801 A JP 2016501801A JP 2016512554 A5 JP2016512554 A5 JP 2016512554A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- seq
- binding fragment
- rsv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 59
- 102000036639 antigens Human genes 0.000 claims 59
- 108091007433 antigens Proteins 0.000 claims 59
- 230000027455 binding Effects 0.000 claims 50
- 239000012634 fragment Substances 0.000 claims 49
- 125000003275 alpha amino acid group Chemical group 0.000 claims 26
- 241000725643 Respiratory syncytial virus Species 0.000 claims 24
- 241000351643 Metapneumovirus Species 0.000 claims 12
- 208000024891 symptom Diseases 0.000 claims 12
- 208000015181 infectious disease Diseases 0.000 claims 11
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 6
- 206010019280 Heart failures Diseases 0.000 claims 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 6
- 239000004473 Threonine Substances 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 230000001684 chronic effect Effects 0.000 claims 6
- 229960000402 palivizumab Drugs 0.000 claims 6
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 6
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 6
- 229960005486 vaccine Drugs 0.000 claims 6
- 230000003472 neutralizing effect Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims 4
- 208000000059 Dyspnea Diseases 0.000 claims 4
- 206010013975 Dyspnoeas Diseases 0.000 claims 4
- 206010062016 Immunosuppression Diseases 0.000 claims 4
- 208000019693 Lung disease Diseases 0.000 claims 4
- 208000028831 congenital heart disease Diseases 0.000 claims 4
- 230000001506 immunosuppresive effect Effects 0.000 claims 4
- 208000018360 neuromuscular disease Diseases 0.000 claims 4
- 241000712461 unidentified influenza virus Species 0.000 claims 4
- 208000037656 Respiratory Sounds Diseases 0.000 claims 3
- 241000144290 Sigmodon hispidus Species 0.000 claims 3
- 206010047924 Wheezing Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 230000002685 pulmonary effect Effects 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 206010011224 Cough Diseases 0.000 claims 2
- 208000005156 Dehydration Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 206010028735 Nasal congestion Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 208000008784 apnea Diseases 0.000 claims 2
- 230000004596 appetite loss Effects 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 2
- 230000007547 defect Effects 0.000 claims 2
- 230000018044 dehydration Effects 0.000 claims 2
- 238000006297 dehydration reaction Methods 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 230000007813 immunodeficiency Effects 0.000 claims 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims 2
- 230000001861 immunosuppressant effect Effects 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 208000019017 loss of appetite Diseases 0.000 claims 2
- 235000021266 loss of appetite Nutrition 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229960001521 motavizumab Drugs 0.000 claims 2
- 230000003387 muscular Effects 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 208000013220 shortness of breath Diseases 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 238000010171 animal model Methods 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims 1
- 210000000748 cardiovascular system Anatomy 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 230000006996 mental state Effects 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782215P | 2013-03-14 | 2013-03-14 | |
| US61/782,215 | 2013-03-14 | ||
| US201361911093P | 2013-12-03 | 2013-12-03 | |
| US61/911,093 | 2013-12-03 | ||
| PCT/US2014/025259 WO2014159822A2 (en) | 2013-03-14 | 2014-03-13 | Human antibodies to respiratory syncytial virus f protein and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512554A JP2016512554A (ja) | 2016-04-28 |
| JP2016512554A5 true JP2016512554A5 (OSRAM) | 2017-03-30 |
| JP6537492B2 JP6537492B2 (ja) | 2019-07-03 |
Family
ID=50391532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501801A Active JP6537492B2 (ja) | 2013-03-14 | 2014-03-13 | 呼吸器合胞体ウイルスｆタンパク質に対するヒト抗体及びその使用方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9447173B2 (OSRAM) |
| EP (1) | EP2968534B1 (OSRAM) |
| JP (1) | JP6537492B2 (OSRAM) |
| KR (1) | KR102211907B1 (OSRAM) |
| CN (1) | CN105050622B (OSRAM) |
| AU (1) | AU2014244411B2 (OSRAM) |
| BR (1) | BR112015019066A2 (OSRAM) |
| CA (1) | CA2904995A1 (OSRAM) |
| CL (1) | CL2015002570A1 (OSRAM) |
| EA (1) | EA034767B1 (OSRAM) |
| IL (1) | IL240067A0 (OSRAM) |
| MX (1) | MX360253B (OSRAM) |
| MY (1) | MY174772A (OSRAM) |
| PH (1) | PH12015501558B1 (OSRAM) |
| SG (2) | SG11201505338RA (OSRAM) |
| TW (1) | TWI659968B (OSRAM) |
| UY (1) | UY35416A (OSRAM) |
| WO (1) | WO2014159822A2 (OSRAM) |
| ZA (1) | ZA201504952B (OSRAM) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI659968B (zh) * | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| SG11201702699TA (en) | 2014-10-10 | 2017-04-27 | Ablynx Nv | Inhalation device for use in aerosol therapy of respiratory diseases |
| RU2017115670A (ru) | 2014-10-10 | 2018-11-15 | Аблинкс Н.В. | Лечение инфекции рсв |
| US9340604B1 (en) * | 2014-10-29 | 2016-05-17 | Aridis Pharmaceuticals, Inc. | Human monoclonal antibody specific for the F protein of respiratory syncytial virus (RSV) |
| CN107810231B (zh) | 2015-06-25 | 2020-10-16 | Sabic环球技术有限责任公司 | 包含直链低密度聚乙烯的聚合物组合物 |
| CN107922455A (zh) * | 2015-07-02 | 2018-04-17 | 春季银行制药股份有限公司 | 用于治疗病毒感染的组合物和方法 |
| TW202440903A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（一） |
| JO3555B1 (ar) | 2015-10-29 | 2020-07-05 | Merck Sharp & Dohme | جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري |
| CN106496324B (zh) * | 2015-11-30 | 2020-01-14 | 天津昊免生物技术有限公司 | 一种抗呼吸道合胞病毒的全人源抗体 |
| EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| CA3040893A1 (en) | 2016-10-21 | 2018-04-26 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
| CN110035771B (zh) * | 2016-10-21 | 2024-03-08 | 阿迪马布有限责任公司 | 抗呼吸道合胞病毒抗体及其产生和使用方法 |
| WO2018075954A2 (en) | 2016-10-21 | 2018-04-26 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| EP3967765A1 (en) | 2017-07-06 | 2022-03-16 | FrieslandCampina Nederland B.V. | Cell culture process for making a glycoprotein |
| US11725045B2 (en) * | 2017-10-13 | 2023-08-15 | Mapp Biopharmaceutical, Inc. | Anti-respiratory syncytial virus antibodies, methods of their generation and use |
| WO2019126123A1 (en) | 2017-12-22 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
| AU2019215363A1 (en) | 2018-01-31 | 2020-07-23 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing size and charge variant drug product impurities |
| CN111936513A (zh) * | 2018-01-31 | 2020-11-13 | 威斯塔解剖学和生物学研究所 | 用于抗呼吸道合胞病毒的核酸抗体构筑体 |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| KR20200127979A (ko) | 2018-02-28 | 2020-11-11 | 리제너론 파마슈티칼스 인코포레이티드 | 바이러스 오염물질을 확인하기 위한 시스템 및 방법 |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| EP4317959A3 (en) | 2018-03-19 | 2024-03-27 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| BR112020026348A2 (pt) | 2018-08-30 | 2021-03-30 | Regeneron Pharmaceuticals, Inc. | Método para avaliar a estequiometria e distribuição de tamanho de complexos de proteínas, para selecionar um medicamento de proteína principal e para caracterizar complexos de proteínas, e, composição farmacêutica |
| AU2019343952A1 (en) * | 2018-09-21 | 2021-04-22 | Mucommune, Llc | Synthetic binding agents for limiting permeation through mucus |
| CN110016079B (zh) * | 2018-12-18 | 2019-12-24 | 珠海泰诺麦博生物技术有限公司 | 抗呼吸道合胞病毒的中和抗体及其应用 |
| KR20210114927A (ko) | 2019-01-16 | 2021-09-24 | 리제너론 파마슈티칼스 인코포레이티드 | 이황화 결합을 특징 짓는 방법 |
| CN111606993B (zh) * | 2019-02-26 | 2022-06-28 | 中国科学院上海生命科学研究院 | 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用 |
| MX2021013519A (es) | 2019-05-13 | 2021-12-10 | Regeneron Pharma | Ensayos de union de ligandos competitivos mejorados. |
| CN114667450B (zh) | 2019-09-24 | 2025-05-02 | 里珍纳龙药品有限公司 | 用于色谱介质的使用和再生的系统及方法 |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| US11730793B2 (en) | 2019-11-25 | 2023-08-22 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| EP4354145B1 (en) | 2020-01-21 | 2025-09-17 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
| CA3192999A1 (en) | 2020-08-31 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
| FR3114970B1 (fr) * | 2020-10-08 | 2023-06-30 | Univ Tours | Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires |
| KR20230113280A (ko) | 2020-11-25 | 2023-07-28 | 리제너론 파마슈티칼스 인코포레이티드 | 비수성 멤브레인 유화법을 사용한 지속 방출 제형 |
| CN116710124A (zh) | 2020-12-17 | 2023-09-05 | 瑞泽恩制药公司 | 包封蛋白质的微凝胶的制造 |
| US12031151B2 (en) | 2021-01-20 | 2024-07-09 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
| AR125585A1 (es) | 2021-03-03 | 2023-08-02 | Regeneron Pharma | Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas |
| MX2023010794A (es) | 2021-03-26 | 2023-10-25 | Regeneron Pharma | Metodos y sistemas para el desarrollo de protocolos de mezcla. |
| CA3220848A1 (en) | 2021-06-01 | 2022-12-08 | Timothy Riehlman | Microchip capillary electrophoresis assays and reagents |
| TW202326138A (zh) | 2021-09-08 | 2023-07-01 | 美商再生元醫藥公司 | 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法 |
| JP2024531800A (ja) | 2021-09-20 | 2024-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗体の不均一性を制御する方法 |
| KR20240090312A (ko) | 2021-10-07 | 2024-06-21 | 리제너론 파아마슈티컬스, 인크. | Ph 미터 보정 및 교정 |
| TW202323817A (zh) | 2021-10-07 | 2023-06-16 | 美商再生元醫藥公司 | Ｐｈ建模及控制之系統及方法 |
| CA3236367A1 (en) | 2021-10-26 | 2023-05-04 | Michelle Lafond | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
| JP2025508233A (ja) | 2022-03-18 | 2025-03-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ポリペプチド変異体を分析するための方法およびシステム |
| WO2024130048A1 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| TW202445126A (zh) | 2023-01-25 | 2024-11-16 | 美商再生元醫藥公司 | 基於質譜法之體內共表現抗體之表徵 |
| TW202445138A (zh) | 2023-02-01 | 2024-11-16 | 美商再生元醫藥公司 | 用於生物巨分子分析之具質譜法的不對稱流場流分離 |
| TW202446462A (zh) | 2023-02-22 | 2024-12-01 | 美商再生元醫藥公司 | 系統適用性參數及管柱老化 |
| TW202508625A (zh) | 2023-05-01 | 2025-03-01 | 美商再生元醫藥公司 | 使用苯酚或苯甲醇之多劑量抗體藥物產品 |
| WO2025054406A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| US20250095773A1 (en) | 2023-09-18 | 2025-03-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| WO2025072597A2 (en) | 2023-09-29 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Lyophilization using controlled nucleation |
| US20250129117A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| WO2025096932A1 (en) | 2023-11-02 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025104604A1 (en) | 2023-11-14 | 2025-05-22 | Janssen Pharmaceuticals, Inc. | Anti-respiratory syncytial virus antibodies and uses thereof |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| WO2025194126A1 (en) * | 2024-03-15 | 2025-09-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Respiratory syncytial virus (rsv) g and f antibodies with high rsv-neutralizing potency |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
| DE69332643T2 (de) | 1992-09-16 | 2003-11-27 | The Scripps Research Institute, La Jolla | Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus |
| US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| WO1997010846A1 (en) | 1995-09-18 | 1997-03-27 | Intracel Corporation | Neutralizing monoclonal antibodies to respiratory syncytial virus |
| AR030019A1 (es) | 1999-05-18 | 2003-08-13 | Smithkline Beecham Corp | Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m |
| US6750008B1 (en) * | 1999-07-09 | 2004-06-15 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission |
| DK1265928T3 (da) | 2000-01-27 | 2010-11-15 | Medimmune Llc | RSV-neutraliserende antistoffer med ultra høj affinitet |
| EP2341075A1 (en) | 2000-03-01 | 2011-07-06 | MedImmune, LLC | Antibodies binding to the f protein of a respiratory syncytial virus (rsv) |
| US6855493B2 (en) * | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US20060083741A1 (en) | 2004-10-08 | 2006-04-20 | Hoffman Rebecca S | Treatment of respiratory syncytial virus (RSV) infection |
| AU2007222798A1 (en) * | 2006-03-06 | 2007-09-13 | Symphogen A/S | Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| RU2526517C2 (ru) | 2007-10-25 | 2014-08-20 | Треллис Байосайенс,Инк. | Антитела против g-белка распираторно-синцитиального вируса (rsv) |
| WO2010087927A2 (en) * | 2009-02-02 | 2010-08-05 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
| EP4218799A1 (en) | 2009-07-15 | 2023-08-02 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
| JP5762408B2 (ja) | 2009-08-13 | 2015-08-12 | クルセル ホランド ベー ヴェー | ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法 |
| US20110097358A1 (en) | 2009-10-12 | 2011-04-28 | Techno Vax, Inc. | RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs) |
| CN102850454B (zh) * | 2011-09-27 | 2014-06-25 | 上海博沃生物科技有限公司 | 抗呼吸道合胞病毒的人单克隆抗体 |
| PL2828293T3 (pl) | 2012-03-20 | 2018-03-30 | Humabs Biomed S.A. | Przeciwciała, które neutralizują RSV, MPV i PVM oraz ich zastosowania |
| AU2014212268B2 (en) | 2013-02-01 | 2018-07-19 | Medimmune, Llc | Respiratory Syncytial Virus F protein epitopes |
| TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 |
| WO2015010792A1 (en) | 2013-07-24 | 2015-01-29 | Humabs Biomed Sa | Antibodies that potently neutralize rsv and uses thereof |
-
2014
- 2014-03-12 TW TW103108584A patent/TWI659968B/zh not_active IP Right Cessation
- 2014-03-13 EA EA201591771A patent/EA034767B1/ru unknown
- 2014-03-13 JP JP2016501801A patent/JP6537492B2/ja active Active
- 2014-03-13 EP EP14714125.3A patent/EP2968534B1/en active Active
- 2014-03-13 SG SG11201505338RA patent/SG11201505338RA/en unknown
- 2014-03-13 UY UY0001035416A patent/UY35416A/es not_active Application Discontinuation
- 2014-03-13 SG SG10201610336QA patent/SG10201610336QA/en unknown
- 2014-03-13 KR KR1020157021198A patent/KR102211907B1/ko not_active Expired - Fee Related
- 2014-03-13 CN CN201480014354.XA patent/CN105050622B/zh not_active Expired - Fee Related
- 2014-03-13 MX MX2015009416A patent/MX360253B/es active IP Right Grant
- 2014-03-13 WO PCT/US2014/025259 patent/WO2014159822A2/en not_active Ceased
- 2014-03-13 BR BR112015019066A patent/BR112015019066A2/pt not_active IP Right Cessation
- 2014-03-13 US US14/207,797 patent/US9447173B2/en active Active
- 2014-03-13 AU AU2014244411A patent/AU2014244411B2/en not_active Ceased
- 2014-03-13 MY MYPI2015702227A patent/MY174772A/en unknown
- 2014-03-13 CA CA2904995A patent/CA2904995A1/en not_active Abandoned
-
2015
- 2015-07-09 ZA ZA2015/04952A patent/ZA201504952B/en unknown
- 2015-07-13 PH PH12015501558A patent/PH12015501558B1/en unknown
- 2015-07-21 IL IL240067A patent/IL240067A0/en unknown
- 2015-09-10 CL CL2015002570A patent/CL2015002570A1/es unknown
-
2016
- 2016-08-05 US US15/229,567 patent/US10125188B2/en active Active
-
2018
- 2018-10-15 US US16/160,374 patent/US20190031741A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512554A5 (OSRAM) | ||
| JP2010528601A5 (OSRAM) | ||
| TWI659968B (zh) | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 | |
| JP5734988B2 (ja) | Ｒｓｖ特異的結合分子 | |
| RU2015136392A (ru) | Композиции и способы, основанные на нейтрализующих антителах, доставляемых интраназально, для улучшенной терапевтической эффективности | |
| JP2020518599A5 (OSRAM) | ||
| Mejias et al. | Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection | |
| Verwey et al. | Review and update of active and passive immunization against respiratory syncytial virus | |
| JP2012504955A5 (OSRAM) | ||
| JP2011528902A5 (OSRAM) | ||
| JP2018506966A5 (OSRAM) | ||
| JP2018535650A5 (OSRAM) | ||
| JP2011155980A5 (OSRAM) | ||
| JP2017507139A5 (OSRAM) | ||
| JP2014500009A5 (OSRAM) | ||
| JP2012525128A5 (OSRAM) | ||
| JP2015522252A5 (OSRAM) | ||
| JP2014524748A5 (OSRAM) | ||
| JP2013543384A5 (OSRAM) | ||
| JP2019534003A5 (OSRAM) | ||
| CN1132516A (zh) | 抗呼吸道合胞体病毒的单克隆IgA抗体 | |
| Diethelm-Varela et al. | New developments and challenges in antibody-based therapies for the respiratory syncytial virus | |
| JP2019162119A5 (OSRAM) | ||
| Li et al. | Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue | |
| Bergeron et al. | Immunogenicity and protective efficacy of an RSV G S177Q central conserved domain nanoparticle vaccine |